LePure Biotech’s Series C Investment

Paul, Weiss, Rifkind, Wharton & Garrison advised General Atlantic on the deal. Shanghai LePure Biotech Co., Ltd. (LePure Biotech), a China-based single-use solutions provider for biopharmaceutical...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here